论文部分内容阅读
目的 评价海藻酸钠和右旋糖苷(SAD)作为载体溶液加抗癌药物治疗中晚期肝癌的临床疗效。方法 抗癌药物加SAD和单纯抗癌药物灌注(TAI)对65例TAE禁忌患者介入治疗。结果 SAD提高抗癌药物于肿瘤组织的有效浓度,延长作用时间(P<0.01);治疗组1年生存率49.03％,平均生存期11.86个月,对照组1年生存率24.17％,平均生存期6.91个月(P<0.01);SAD在肝动脉释药过程中引起一过性栓塞,但副反应小,无严重并发症及死亡病例出现。结论 抗癌药物加SAD具有较TAI更为积极有效的治疗作用。
Objective To evaluate the clinical efficacy of sodium alginate and dextran (SAD) as carrier solution plus anticancer drug in the treatment of advanced liver cancer. Methods 65 patients with TAE taboo were treated with anti-cancer drugs plus SAD and TAI alone. Results SAD increased the effective concentration of anti-cancer drugs in tumor tissues and prolonged the action time (P <0.01). The 1-year survival rate and the mean survival time of the treatment group were 49.03% and 11.86 months respectively. The 1-year survival rate was 24.17% 6.91 months (P <0.01). SAD caused a transient embolization in the course of hepatic artery drug delivery, but with fewer side effects and no serious complications and deaths. Conclusion The anti-cancer drugs plus SAD have a more positive and effective therapeutic effect than TAI.